Cost-Effectiveness Analysis of Relmacabtagene Autoleucel for Relapsed or Refractory Large B-Cell Lymphoma in China.

Abstract

OBJECTIVES:

Relmacabtagene autoleucel (relma-cel) was recently approved in China for treating relapsed or refractory large B-cell lymphoma (r/r LBCL). We conducted a cost-effectiveness analysis from the perspective of Chinese healthcare system.

METHODS:

A mixture-cure model was developed to project life-years (LYs), quality-adjusted LYs (QALYs), and overall direct cost with a lifetime horizon for patients with r/r LBCL treated with relma-cel versus salvage chemotherapy. Patient-level data from RELIANCE trial and published data from Collaborative Trial in Relapsed Aggressive Lymphoma extension study were used to inform the model. The incremental cost-effectiveness ratio (ICER) was estimated and cost-effectiveness was evaluated at the willingness-to-pay threshold of 3 times the national gross domestic product per capita.

RESULTS:

The model projected that treatment with relma-cel was associated with incremental gains of 5.11 LYs and 5.26 QALYs compared with salvage chemotherapy at an increased cost of ¥1 067 430 (∼$154 152), resulting in an ICER of ¥203 137 (∼$29 435) per QALY. The model was most sensitive to the uncertainty around the estimated cure rate. The ICER of relma-cel was within the willingness-to-pay threshold in the base case and the probability of relma-cel treatment being considered cost-effective was approximately 74%.

CONCLUSIONS:

Compared with salvage chemotherapy, treatment with relma-cel for r/r LBCL in patients who have failed at least 2 lines of systemic therapy is within the cost-effective range from the perspective of Chinese healthcare system and represents a good use of healthcare resources.

• Authors: Ziyi Lin, Chenyu Zuo, Yifan Jiang, Wen Su, Xing Yao, Yu Man, Qiong Wu, Jianwei Xuan
• Journal: Value in health regional issues (Value Health Reg Issues) Vol. 37 Pg. 41-48 (Sep 2023) ISSN: 2212-1102 [Electronic] United States
• PMID: 37209540 (Publication Type: Journal Article)
• Copyright: Copyright © 2023 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.

Chemical References

• relmacabtagene autoleucel

Topics

• Humans
• Cost-Effectiveness Analysis
• Cost-Benefit Analysis
• Lymphoma, B-Cell (drug therapy)
• China